@RB_Cavalcanti @jddneary @ASPREE_aus @alisonlaiMD We repeated the study, this time using statins, and found almost identical results. https://t.co/ZcpbwjrNgQ #ebm
RT @JournalGIM: @fralickmike & @akesselheim demonstrate that trials of #statins with run-ins provide similar estimates for benefit and harm…
RT @JournalGIM: @fralickmike & @akesselheim demonstrate that trials of #statins with run-ins provide similar estimates for benefit and harm…
@fralickmike & @akesselheim demonstrate that trials of #statins with run-ins provide similar estimates for benefit and harm as trials without https://t.co/BnRZBHdQqX
RT @FralickMike: Our (@EmilyVBartsch @akesselheim & Abdurrahman) study on the impact of run-in studies using another class of medications…
RT @FralickMike: Our (@EmilyVBartsch @akesselheim & Abdurrahman) study on the impact of run-in studies using another class of medications…
RT @EmilyVBartsch: my first paper with @FralickMike is now available in @JournalGIM! https://t.co/ZFIEqu6UeB
my first paper with @FralickMike is now available in @JournalGIM! https://t.co/ZFIEqu6UeB
Our (@EmilyVBartsch @akesselheim & Abdurrahman) study on the impact of run-in studies using another class of medications is out in @JGIM. For trials of statins, RCTs with run-ins (compared to RCTs w/o) provided similar findings for efficacy and safety
Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety https://t.co/6lTGRJlEDw